01:24 AM EDT, 09/30/2026 (MT Newswires) -- Roche's (RO.SW) new drug application for its investigational treatment for multiple sclerosis, fenebrutinib, was accepted by the US Food and Drug Administration. The acceptance was supported by the Swiss drugmaker's Phase 3 Fenhance 1 and 2 RMS trials and the Phase 3 Fentrepid PPMS study, according to a Wednesday release. The company noted that if the application is approved, fenebrutinib would be the first oral Bruton's tyrosine kinase inhibitor therapy for relapsing multiple sclerosis and primary progressive multiple sclerosis.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.